Sun Pharma Latest Share Price, Insights and Trends

Sun Pharmaceutical Industries Ltd. is an Indian multinational pharmaceutical company that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients.

Sun Pharma was founded in 1983 in Vapi by Dilip Shanghvi. It is headquartered in Mumbai and has subsidiaries including Ranbaxy Laboratories and Taro Pharmaceutical Industries Ltd..

Sun Pharma is one of the world’s largest generic pharmaceutical companies and the number one specialty generic pharmaceutical company in India. They offer high-quality, affordable medicines to customers and patients in over 100 countries.

Some of Sun Pharma’s products include:
Volini, Revital, Neurobion, Zandu, Vicks, Abzorb, Evion.

Sun Pharma’s CSR efforts focus on serving underprivileged communities and their priority areas include health, education, drinking water, and sanitation.

.
* About Sun Pharma information is from various sources on the internet.
( March 2024 ).
Please verify the official website of Sun Pharma for the latest updated information.

Please visit
https://investinstocks.co.in/find-any-stock-of-Indian-stock-market/
to know about any company.

.

What’s your view on this stock? Please comment.

*Data is only for info. Not Buy or Sell advice.
*** Don’t waste your hard earned money by trading in stock market.
Don’t trade.
100% of the traders will loose money in the market.
“Invest in stock market.”
Consult financial expert before investing.
.

Results Declared Stocks 2025 Dec

From Sun Pharmaceutical Industries Limited website :

Sun Pharmaceutical Industries Ltd. (Sun Pharma) is the fourth largest specialty generic pharmaceutical company in the world with global revenues of over US$ 5.1 billion. Supported by more than 40 manufacturing facilities, we provide high-quality, affordable medicines, trusted by healthcare professionals and patients, to more than 100 countries across the globe.

Diversified Specialty and Generics Portfolio

We manufacture and market a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies. It includes generics, branded generics, specialty, complex or difficult to make technology-intensive products, over-the-counter (OTC), antiretrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and Intermediates. Our broad portfolio of more than 2000 high quality molecules covers multiple dosage forms, including tablets, capsules, injectables, inhalers, ointments, creams, and liquids.

Every year, we sell over 30 billion doses covering neuro-psychiatry, cardiology, gastroenterology, anti-infectives, diabetology, oncology, ophthalmology, dermatology, urology, nephrology and respiratory among others.

Driven by Innovation

The first among Indian pharmaceutical companies to realise and embrace the importance of investing in research, we invest up to 7-8% of our global revenues into Research and Development (R&D) every year.
Our core strength lies in our ability to excel in developing generics and technologically complex products backed by our dedicated teams in formulations, process chemistry, and analytical development.

Our capabilities extend beyond the development of differentiated products, including liposomal products, inhalers, lyophilized injections, nasal sprays, and controlled release dosage forms.

Our R&D team comprises over 2,700 people.

Global Footprint

From humble beginnings in 1983, Sun Pharma has grown to become one of the largest generic pharmaceutical companies worldwide. We are the largest pharmaceutical company in India.

In the US, we are among the top 10 generic pharmaceutical companies and are ranked second by prescriptions in the generic dermatology market.

We are the largest Indian company in emerging markets with a presence in over 80 markets. Brazil, Mexico, Russia, Romania and South Africa are some of our key emerging markets.

We are present across all major markets in Western Europe, Canada, Australia, New Zealand, Japan and China among others.